CHINA PHARMA HOLDINGS, INC. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 99/100
What the filing says
China Pharma Holdings priced a registered direct offering on July 22, 2026, selling 2.5 million shares at $2.00 per share for $5 million gross proceeds. The offering was conducted under an effective Form S-3 registration statement (File No. 333-276481, effective February 14, 2024). FT Global Capital, Inc. served as exclusive placement agent, earning a 7% placement fee ($350,000). Net proceeds are designated for working capital and general corporate purposes.
Why this rating
At $4.3M market cap, a $5M capital raise is massive—116% of company size. Extreme dilution risk: 2.5M new shares at $2 versus unknown existing shares; lock-up on 70% of existing shares (restricted holders) indicates prior distress. Material adverse effect on per-share value inevitable.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.